Since the phase III trials were assessed in a molecularly unselected population, one possible factor contributing to this inconsistency is the lack of predictive biomarkers to identify patients who tend to develop EGFR-dependent tumor growth and drug resistance. Here, EGFR is linked to neoplasm.